Novo Nordisk Inc initiated a recall of Victoza (liraglutide) injection on March 22, 2021. The recall involved 18 mg/3 mL (6 mg/mL) sample pen-injectors, not for resale, distributed under NDC 0169-4060-90 and 0169-4060-99.
The U.S. FDA classified this action as a Class II recall. The stated reason was temperature abuse. Product samples were stored at temperatures below 32 degrees Fahrenheit, which did not meet required storage conditions.
According to the recall record, this storage deviation could cause a lack of efficacy and could damage the cartridge and pen-injectors. The recall status is listed as terminated.
This recall record reflects a specific batch of sample product affected by a storage condition issue during distribution. It does not describe a broader safety finding about liraglutide as an approved therapy. Readers can consult the compound overview for additional context on liraglutide's regulatory status and background.